Biogen and Sage Therapeutics do not plan to conduct further studies for their neurological disorder drug after it failed in a mid-stage trial, the drugmakers said on Wednesday.
Tag Archive for: Zurzuvae
Despite launching with just days left in 2023, Sage Therapeutics’ postpartum depression therapy Zurzuvae made $1.6 million in sales, the Massachusetts-based biotech reported in Wednesday’ s fourth-quarter and full-year earnings results.
According to Sage Therapeutics, U.S. wholesalers are expected to pay almost $16,000 for the full 14-day treatment.
The FDA’s decision to decline the drug’s approval for a much larger cohort of patients with clinical depression, along with strict safety warnings for its use in PPD, is still a “strike against (Biogen’s) management”, Baird analyst Brian Skorney said.
Having access to an oral medication will be a beneficial option for many of women coping with PPD and having extreme, and sometimes life-threatening, feelings, says the FDA.